Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Rafael Fonseca MD
Rafael Fonseca MD Editor-in-Chief
See All Experts
featured
Published in Oncology

Journal Scan / Research · June 15, 2019

5-Year Overall Survival for Patients With Advanced NSCLC Treated With Pembrolizumab

Journal of Clinical Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Sarah Goldberg MD, MPH

Journal of Clinical Oncology
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
J. Clin. Oncol 2019 Jun 02;[EPub Ahead of Print], EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, JP Eder, AS Balmanoukian, C Aggarwal, L Horn, A Patnaik, M Gubens, SS Ramalingam, E Felip, JW Goldman, C Scalzo, E Jensen, DA Kush, R Hui

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated